

## Special Issue

# Antibacterial Approaches to Reduce the Use of Antibiotics

### Message from the Guest Editor

Antimicrobial resistance (AMR) is a slow-moving pandemic and one of the leading causes of death worldwide. While bacterial resistance continues to increase with the ongoing misuse of antibiotics, limited treatment options remain available, yet very few new antibiotics are being developed. As such, novel non-traditional antibacterial approaches that would reduce the use of antibiotics are much needed. This Special Issue of *Antibiotics* encourages the submission of original research papers, short communications, reviews, case reports, and perspectives that concentrate on but are not limited to:

- Combination therapies;
- Vaccines;
- Bacteriophages;
- Immunomodulators;
- Host-targeted antibacterials;
- Non-medical approaches to limit antibiotic use;
- Gut microbiota modulation;
- Inhibitors of resistance mechanisms.

The candidate submissions for this Special Issue must be written in the context of reducing antibiotic use.

---

### Guest Editor

Dr. Daniel M. Czyz

Department of Microbiology and Cell Science, University of Florida,  
Gainesville, FL, USA

---

### Deadline for manuscript submissions

closed (29 February 2024)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/111731](https://mdpi.com/si/111731)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)